Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

苯拉唑马布 医学 安慰剂 恶化 哮喘 嗜酸性粒细胞增多症 临床终点 美波利祖马布 内科学 嗜酸性粒细胞 随机对照试验 病理 替代医学
作者
Eugene R. Bleecker,J. Mark FitzGerald,Pascal Chanez,Alberto Papi,Steven F. Weinstein,Peter Barker,Stephanie Sproule,Geoffrey Gilmartin,Magnus Aurivillius,Viktoría Werkström,Mitchell Goldman
出处
期刊:The Lancet [Elsevier BV]
卷期号:388 (10056): 2115-2127 被引量:1195
标识
DOI:10.1016/s0140-6736(16)31324-1
摘要

Eosinophilia is associated with worsening asthma severity and decreased lung function, with increased exacerbation frequency. We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor α that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia.We did a randomised, double-blind, parallel-group, placebo-controlled phase 3 study at 374 sites in 17 countries. We recruited patients (aged 12-75 years) with a physician-based diagnosis of asthma for at least 1 year and at least two exacerbations while on high-dosage inhaled corticosteroids and long-acting β2-agonists (ICS plus LABA) in the previous year. Patients were randomly assigned (1:1:1) by an interactive web-based voice response system to benralizumab 30 mg either every 4 weeks (Q4W) or every 8 weeks (Q8W; first three doses every 4 weeks) or placebo Q4W for 48 weeks as add on to their standard treatment. Patients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per μL and less than 300 cells per μL. All patients and investigators involved in patient treatment or clinical assessment were masked to treatment allocation. The primary endpoint was annual exacerbation rate ratio versus placebo, and key secondary endpoints were prebronchodilator forced expiratory volume in 1 s (FEV1) and total asthma symptom score at week 48, for patients with blood eosinophil counts of at least 300 cells per μL. Efficacy analyses were by intention to treat (based on the full analysis set); safety analyses included patients according to study drug received. This study is registered with ClinicalTrials.gov, number NCT01928771.Between Sept 19, 2013, and March 16, 2015, 2681 patients were enrolled, 1205 of whom met the study criteria and were randomly assigned: 407 to placebo, 400 to benralizumab 30 mg Q4W, and 398 to benralizumab 30 mg Q8W. 267 patients in the placebo group, 275 in the benralizumab 30 mg Q4W group, and 267 in the benralizumab 30 mg Q8W group had blood eosinophil counts at least 300 cells per μL and were included in the primary analysis population. Compared with placebo, benralizumab reduced the annual asthma exacerbation rate over 48 weeks when given Q4W (rate ratio 0·55, 95% CI 0·42-0·71; p<0·0001) or Q8W (0·49, 0·37-0·64; p<0·0001). Both benralizumab dosing regimens significantly improved prebronchodilator FEV1 in patients at week 48 compared with placebo (least-squares mean change from baseline: Q4W group 0·106 L, 95% CI 0·016-0·196; Q8W group 0·159 L, 0·068-0·249). Compared with placebo, asthma symptoms were improved by the Q8W regimen (least-squares mean difference -0·25, 95% CI -0·45 to -0·06), but not the Q4W regimen (-0·08, -0·27 to 0·12). The most common adverse events were worsening asthma (105 [13%] of 797 benralizumab-treated patients vs 78 [19%] of 407 placebo-treated patients) and nasopharyngitis (93 [12%] vs 47 [12%]).These results confirm the efficacy and safety of benralizumab for patients with severe asthma and elevated eosinophils, which are uncontrolled by high-dosage ICS plus LABA, and provide support for benralizumab to be an additional option to treat this disease in this patient population.AstraZeneca and Kyowa Hakko Kirin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小张发布了新的文献求助30
刚刚
dengdengdeng发布了新的文献求助10
刚刚
刚刚
愉快幻悲完成签到,获得积分10
2秒前
ecoli发布了新的文献求助10
2秒前
周奕迅发布了新的文献求助10
3秒前
小宝爸爸发布了新的文献求助10
4秒前
yang完成签到,获得积分10
5秒前
慕青应助灰底爆米花采纳,获得10
5秒前
852应助nicewink采纳,获得10
6秒前
dengdengdeng完成签到,获得积分10
7秒前
叮当发布了新的文献求助10
8秒前
bkagyin应助keyanrubbish采纳,获得30
10秒前
xtt完成签到,获得积分10
12秒前
Aimee完成签到 ,获得积分10
14秒前
14秒前
小马甲应助Arui采纳,获得10
14秒前
大个应助hg08采纳,获得10
16秒前
17秒前
DELI完成签到 ,获得积分10
18秒前
隐形曼青应助科研通管家采纳,获得10
19秒前
酷波er应助科研通管家采纳,获得10
19秒前
YamDaamCaa应助科研通管家采纳,获得30
19秒前
ED应助科研通管家采纳,获得10
19秒前
大模型应助科研通管家采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
搜集达人应助科研通管家采纳,获得10
19秒前
kecheng应助科研通管家采纳,获得10
19秒前
YamDaamCaa应助科研通管家采纳,获得30
19秒前
19秒前
19秒前
19秒前
orixero应助sss采纳,获得10
21秒前
21秒前
周奕迅完成签到,获得积分20
23秒前
mashichuang发布了新的文献求助10
23秒前
24秒前
keyanrubbish发布了新的文献求助30
25秒前
27秒前
Qenyo发布了新的文献求助10
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
Current Perspectives on Generative SLA - Processing, Influence, and Interfaces 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3991794
求助须知:如何正确求助?哪些是违规求助? 3532981
关于积分的说明 11260197
捐赠科研通 3272241
什么是DOI,文献DOI怎么找? 1805664
邀请新用户注册赠送积分活动 882609
科研通“疑难数据库(出版商)”最低求助积分说明 809405